Company news
60 Degrees Pharmaceuticals, Inc. news in 2024
60 Degrees Pharmaceuticals, Inc.'s news releases, calls and decks from 2024, newest first.
Sixty Degrees Pharmaceuticals and Tufts Medical Center Announce Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention
December 22, 2024
60 Degrees Pharmaceuticals Expands Tafenoquine Clinical Trial for Babesiosis to Brigham and Women’s Hospital
December 10, 2024
60 Degrees Pharmaceuticals Announces Third Quarter 2024 Results
November 13, 2024
60 Degrees Pharmaceuticals Inc. Announces ARAKODA® Promotional Pilot in Advance of Expanded U.S. Launch
October 2, 2024
60 Degrees Pharmaceuticals, Inc. Announces $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules
September 3, 2024
60 Degrees Pharmaceuticals, Inc. Regains Compliance with Nasdaq Listing Requirements
August 27, 2024
60 Degrees Pharmaceuticals Announces Second Quarter 2024 Results
August 13, 2024
60 Degrees Pharma Provides University of Kentucky with Right of Reference to ARAKODA® NDA in Support of SJ733 Phase IIb Study
August 11, 2024
60 Degrees Pharmaceuticals, Inc. Announces 1: 12 Reverse Stock Split
August 5, 2024
60 Degrees Pharmaceuticals Awarded Contract with U.S. Army for ARAKODA® Supply Chain Upgrade Support
July 24, 2024
60 Degrees Pharmaceuticals Signs Clinical Trial Agreements With All Planned Trial Sites for Tafenoquine Babesiosis Study
July 18, 2024
60 Degrees Pharma Announces IRB Approval of Clinical Study of Tafenoquine for Treatment of Babesiosis in Immunocompromised Patients with Persistent Babesia microti Despite Prior Treatment
July 8, 2024
First Patient Enrolled in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis at Tufts Medical Center; First and Only Study of Its Kind
June 26, 2024
60 Degrees Pharmaceuticals Receives FDA Orphan Drug Designation for Tafenoquine for Treatment of Patients with Acute Babesiosis
June 10, 2024
Enrollment in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis to Begin at Tufts Medical Center; First Study of Its Kind
May 29, 2024
60 Degrees Pharmaceuticals Funds Babesia spp Testing in Chronic Fatigue Patient Samples in NC State College of Veterinary Medicine Study
May 19, 2024
60 Degrees Pharmaceuticals Announces First Quarter 2024 Results
May 14, 2024
60 Degrees Pharmaceuticals Outlines Upcoming Clinical Trial of Tafenoquine in Babesiosis in Letter to Journal of Infectious Diseases
May 7, 2024
60 Degrees Pharmaceuticals Receives FDA Comments on Tafenoquine-Babesiosis Clinical Trial Protocol; No Material Changes Required
May 1, 2024
60 Degrees Pharmaceuticals to Sponsor Pilot Study of Tafenoquine for Treatment of Canine Babesiosis
April 2, 2024
60 Degrees Pharmaceuticals Announces Communication from the FDA of Intention to Respond to Tafenoquine-Babesiosis Trial Protocol Submission in April, 2024
March 13, 2024
60 Degrees Pharmaceuticals to Sponsor Pre-Clinical Studies of Tafenoquine Use in Candida spp, Including Candida auris
February 19, 2024
60 Degrees Pharmaceuticals Appoints Kristen Landon as Chief Commercial Officer
February 7, 2024
60 Degrees Pharmaceuticals Announces Closing of $2.4 Million Public Offering
January 30, 2024
60 Degrees Pharmaceuticals Announces Pricing of $2.4 Million Public Offering
January 29, 2024
60 Degrees Pharma Plans Pivotal Babesiosis Study with Tafenoquine Following Jan 17 FDA Meeting
January 21, 2024
60 Degrees Pharma Regains Compliance with Nasdaq Listing Requirements
January 15, 2024